This could start to bring down the cost of brand-name competitors—here's who may get to use it, and one major difference from ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

GLP-1 receptor agonists, such as liraglutide, semaglutide, and exenatide, are designed to replicate the actions of the glucagon-like peptide-1 hormone, which naturally regulates blood sugar and ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who ...